1. Home
  2. RCUS

RCUS

Arcus Biosciences Inc.

Logo Arcus Biosciences Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 12:08pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Founded: 2015 Country:
United States
United States
Employees: N/A City: HAYWARD
Market Cap: 1.5B IPO Year: 2018
Target Price: $41.78 AVG Volume (30 days): 855.7K
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.15 EPS Growth: N/A
52 Week Low/High: $12.95 - $25.47 Next Earning Date: 05-07-2024
Revenue: $117,000,000 Revenue Growth: 4.46%
Revenue Growth (this year): 67.09% Revenue Growth (next year): -13.07%

Share on Social Networks: